Business Wire

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Adopted by Traditional Japanese Brand for Children’s Room Lighting to Support Students’ Learning and Concentration

Share

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global compound semiconductor, announced that its SunLike Series natural spectrum LEDs have been adopted by KOIZUMI Lighting Technology Corp. (“Koizumi”), a traditional Japanese lighting company, for use in lights for children’s rooms and living rooms. SunLike Series natural spectrum LEDs are optimized to support healthy circadian rhythms based on natural sunlight, under which all animals and plants on the earth have evolved over 3.9 billion years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200727005877/en/

Fig. 1. SunLike Series natural spectrum LEDs adopted by Koizumi for children’s room lighting (Photo: Business Wire)

Fig. 1. SunLike Series natural spectrum LEDs adopted by Koizumi for children’s room lighting (Photo: Business Wire)

In designing their children’s room lighting systems, Koizumi has adopted the SunLike Series natural spectrum LEDs, which have been recognized as an innovative technology that produces light that closely matches the spectrum of natural sunlight by a total of ten global lighting awards held in Korea, Europe, China, and the US. The SunLike Series LEDs have three beneficial effects in contrast to conventional LEDs: Eye Better – protection from myopia in children; Study Better – support for students’ learning and concentration; and Sleep Better – improvement in sleep quality.

Based on the results of a comprehensive sleep study conducted by Professor Christian Cajochen and his colleagues at the University of Basel in Switzerland, LED light sources with the same measured intensity and correlated color temperature (CCT), but different spectral output, can have different effects on human behavior and physiology. The study, published in the Journal of Lighting & Research Technology on March 24, 2019, found “evidence that daylight [natural spectrum] LED solution has beneficial effects on visual comfort, daytime alertness, mood, and sleep intensity in healthy volunteers.”

According to the results of a study done by the Bio-Information Laboratory of Seoul National University Hospital in July of 2018, SunLike Series natural spectrum LEDs have been shown to reduce eye discomfort and improve sleep patterns.

In addition, Michael W. Young, Jeffrey C. Hall, and Michael Rosbash, the recipients of the Nobel Prize in Physiology or Medicine in 2017, discovered the molecular mechanism of circadian rhythm, which governs biological clock based on a 24-hour cycle that regulates sleep, eating behavior, and metabolism.

Improved sleep has recently become more important in the midst of the COVID-19 pandemic. Various studies show that high sleep quality can boost immunity, enhancing the ability to resist a particular infection or toxin.

“Our SunLike Series natural spectrum LEDs are an advanced technology that has achieved the highest level of eye safety certification from the International Commission on Illumination as a safe light source with no photo-biological risks. In particular, it helps improve eye comfort and concentration for children,” said a representative at Seoul Semiconductor.

Introduced in June 2017, the SunLike Series natural spectrum LEDs are an advanced light source that combines the latest optical and compound semiconductor technology of Seoul Semiconductor with Toshiba Materials’ TRI-R® technology. TRI-R, supported by Toshiba Materials, finds in the definition “The light closest to the sun for human well-being” as its original concept. The sunlight spectrum is developed by the same company and can be reproduced by a white LED light source technology. TRI-R is a registered trademark by the Toshiba Materials Co., LTD.

  • SunLike Recognitions

#

Date

Awards

Location

1

2018

Mar.

Product of the Year Award 2018

from Elektronik Magazine

EU

2

Apr.

The Top 10 MUST SEE Products at 2018 Edison Award

US

3

Aug.

Industry Recognition in 2018 IES Progress Report

US

4

Sep.

Best Application Technology at LpS Award 2018

EU

5

Oct.

Top 15 Engineering Technology

by the National Academy of Engineering of Korea

KR

6

Nov.

The Most Creative LED Technology Award

in OFweek China LED Lighting Awards 2018

CN

7

Nov.

2019 “Top 10 Product” for Sustainable Construction

from BuildingGreen

US

8

Nov.

Enabling Technology of the Year at Lux Award 2018

EU

9

2019

May

A Winner of the Lighting Solution

at German Innovation Award 2019

EU

10

Jun.

Korean President’s Award

at International LED EXPO 2019

KR

About Seoul Semiconductor

Seoul Semiconductor develops and commercializes LEDs for automotive, general illumination, specialty lighting, and backlighting markets. As the second-largest LED manufacturer globally excluding the captive market, Seoul Semiconductor holds more than 10,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; WICOP – a simpler structured package-free LED which provides market leading color uniformity and cost savings at the fixture level, providing high lumen density and design flexibility; NanoDriver Series – the world’s smallest 24W DC LED drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, including all AC LED-related technologies from chip to module and circuit fabrication, and nPola, a new LED product based on GaN-substrate technology that achieves more than ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers more than 90% NTSC. For more information, please visit www.seoulsemicon.com/en.

Contact information

Seoul Semiconductor Inc.
North America
Andrew Smith
Tel: +1 (901) 831-6614
Email: andrew.smith@seoulsemicon.com

Seoul Semiconductor Co., Ltd.
Jeonghee Kim
Tel: +82-70-4391-8311
Email: jeonghee.kim@seoulsemicon.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Global Initiates Expansion into Albania28.10.2020 14:30:00 CETPress release

Andersen Global continues to focus on its expansion strategy in the European region with the addition of KALO & ASSOCIATES in Albania. The firm, founded in 1994 by Managing Partner Perparim Kalo, is a leading law firm in Albania. With a team of eight Partners and 30 professionals, the firm has proven capabilities in banking and finance, corporate, commercial litigation and arbitration, employment, tax, infrastructure, intellectual property, and real estate. In addition to working with large projects and investors and IFIs, including a number of Fortune 500 companies, the firm has contributed to the development of a modern commercial legislation and regulatory framework through involvement in the drafting of laws on secured transactions, financial leasing, pension funds, collective investment funds, telecommunications, concessions, renewable energy and energy efficiency. Additionally, the firm is highly ranked by IFLR1000,Chambers and Legal 500. “As the business environment continues to

Sevan Completes 28,000 Surveys, Reaches Major Milestone28.10.2020 14:00:00 CETPress release

Sevan Multi-Site Solutions, Inc. (Sevan) — a global leader in innovative design, program management, construction services and data analytics — has reached a significant milestone. The company has completed 28,000surveys, adding up to more than 700 million square feet since Sevan’s inception in 2011. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005437/en/ Sevan completes 28,000 surveys, reaches major milestone. More than 700 million square feet surveyed. (Graphic: Business Wire) “Sevan’s surveys have become a thread that runs through many of our program management offerings,” President and CEO Jim Evans said. “One of our strongest traits as a company is that we tailor to the needs of our clients, customize innovative solutions and deliver excellence. It has been incredible to see the growth of our surveys and technology offerings in the past years, and we are grateful we have the opportunity to contribute to the succ

Synergis Adept Named #1 in 21 Rankings on G2’s 2020 Fall Grid Reports28.10.2020 13:21:00 CETPress release

Synergis Software, a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd’s Fall 2020 Grid Reports. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005422/en/ Synergis Adept earns 21 top honors on G2 Crowd's 2020 Fall Grid Reports. (Graphic: Business Wire) The reports, which are based on real customer reviews, highlight Adept’s leadership in ease of use, ease of setup, fastest implementation, best support and best relationship as some of the key differentiators compared to other products on the market. Adept earned Leader status in Product Data Management (PDM) and Enterprise Content Management (ECM), and High Performer status in Construction Drawing Management. “We're committed to helping clients become more efficient, secure and collaborative, and reports like this help us understand what we're

Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-1928.10.2020 13:20:00 CETPress release

Boehringer Ingelheim today announced the initiation of a Phase 2 clinical trial of BI 764198, an inhibitor of TRPC6, a receptor-operated cation channel. This potent and selective inhibitor of TRPC6 may alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19. The aim of therapy with BI 764198 is to reduce the need for ventilator support, to improve patient recovery rate and ultimately to save lives. Boehringer Ingelheim is committed to fighting COVID-19 and contributing with its expertise and resources to develop new therapeutic options for patients suffering from the virus’ severe complications. “COVID-19 can cause serious lung complications, such as viral pneumonia, and in severe cases can lead to acute respiratory distress syndrome (ARDS) and lung failure,” said Dr. Lorraine B. Ware, Ralph and Lulu Oven Endowed Chair and Professor of Medicine, and Pathology, Microbiology and Immunology, Vanderbilt Uni

First Patients Treated with the World’s Smallest Heart Pump, the 9Fr Impella ECP28.10.2020 13:03:00 CETPress release

Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pump in the world. It measures 9 French (Fr) (3 millimeters) in diameter upon insertion and removal from the body. While in the heart, it expands while supporting the heart’s pumping function, providing peak flows greater than 3.5 L/min. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005398/en/ Impella ECP is the world’s smallest heart pump. (Graphic: Business Wire) The first Impella ECP patient was treated by Amir Kaki, MD, an interventional cardiologist and director of mechanical circulatory support at Ascension St. John Hospital in Detroit, part of Ascension Michigan. The patient had severe narrowing of his coronary arteries. Dr. Kaki successfully opened the patient’s arteries by performing several percutaneous interventions with support from Impella ECP

Alira Health and Embleema Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life Sciences28.10.2020 13:00:00 CETPress release

Alira Health, a leading international healthcare and life sciences advisory firm, and Embleema, the innovative software provider for patient-driven healthcare data platforms, today announced a strategic partnership to develop next-generation real-world data solutions aimed at accelerating clinical innovation and improving patient outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201028005026/en/ "Our partnership with Embleema is a critical step in the further development of our real-world evidence capabilities, which connects clinical research, hospital care, and the patient experience,” says Gabriele Brambilla, Chief Executive Officer of Alira Health. Romain Finas, VP of Real World Evidence at Alira Health, adds, “We are excited to offer our clients new solutions for real-world data, which will empower them to better evaluate their treatments and deliver new innovations to patients more quickly.” Robert Chu, Chief Ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom